Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.67 |
| ▸ | CA2 | P00918 | 9/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | STAT3 | P40763 | 2/20 | 0.59 |
| ▸ | MMP2 | P08253 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939620 | 0.87 | MMP2 (0.61) | CA1CA2MMP2NPC1RAB9A | |
| SCHEMBL941037 | 0.86 | MMP2 (0.70) | CA1CA2MMP2CA12CA9 | |
| SCHEMBL940339 | 0.82 | MMP2 (0.65) | CA1CA2MMP2CA12CA9 | |
| SCHEMBL11352041 | 0.82 | CA1 (0.60) | CA1CA2MAPTCA12CA9 | |
| SCHEMBL942182 | 0.81 | CA2 (0.69) | CA1CA2MMP2CA12CA9 | |
| SCHEMBL939843 | 0.81 | MMP2 (0.66) | CA1CA2MMP2CA12CA9 | |
| SCHEMBL27833062 | 0.80 | NPC1 (0.53) | CA1CA2MMP2NPC1RAB9A | |
| SCHEMBL941023 | 0.80 | CA1 (0.70) | CA1CA2MMP2NPC1RAB9A | |
| SCHEMBL28259451 | 0.80 | CA1 (0.74) | CA1CA2MAPTSTAT3NPC1 | |
| SCHEMBL940646 | 0.79 | MMP2 (0.57) | CA1CA2MAPTSTAT3MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8362063-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-8362063-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-8222424-B2 | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-8222424-B2 | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| CN-102036953-A | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| EP-2268612-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | MMP11, MMP10, MMP9 | CA1 2747/4885CA2 1123/4885MAPT 3196/4885 |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | MMP11, MMP10, MMP9 | CA1 2747/4885CA2 1123/4885MAPT 3196/4885 |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | CA1 2740/4885CA2 1073/4885MAPT 3177/4885 |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | CA1 2740/4885CA2 1073/4885MAPT 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.